mianserin has been researched along with Body Weight in 28 studies
Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed an open-label single-institution phase II trial of mirtazapine (15-30 mg by mouth [po] every day [qd]), a tetracyclic antidepressant that may lead to weight gain, for 8 weeks in nondepressed patients with cancer-related cachexia/anorexia (CRCA)." | 9.14 | Phase II trial of mirtazapine for cancer-related cachexia and anorexia. ( Burman, D; Riechelmann, RP; Rodin, G; Tannock, IF; Zimmermann, C, 2010) |
| "To investigate the effect of mirtazapine on tumor growth, food intake, body weight, and nutritional status in gemcitabine-induced mild cachexia." | 7.78 | Intervention of mirtazapine on gemcitabine-induced mild cachexia in nude mice with pancreatic carcinoma xenografts. ( Jia, L; Jiang, SM; Wu, JH, 2012) |
| "To report the use of Mirtazapine in the treatment of anorexia nervosa with depression primarily regarding its propensity for weight gain." | 7.74 | Mirtazapine for anorexia nervosa with depression. ( Baharudin, A; Daud, TI; Jaafar, NR; Rahman, FN, 2007) |
| "We performed an open-label single-institution phase II trial of mirtazapine (15-30 mg by mouth [po] every day [qd]), a tetracyclic antidepressant that may lead to weight gain, for 8 weeks in nondepressed patients with cancer-related cachexia/anorexia (CRCA)." | 5.14 | Phase II trial of mirtazapine for cancer-related cachexia and anorexia. ( Burman, D; Riechelmann, RP; Rodin, G; Tannock, IF; Zimmermann, C, 2010) |
| " Mirtazapine, a widely used antidepressant, induces adverse metabolic effects such as an increase in body weight." | 5.12 | Effect of mirtazapine treatment on body composition and metabolism. ( Deisenhammer, EA; Ebenbichler, CF; Engl, J; Hinterhuber, H; Kramer-Reinstadler, K; Laimer, M; Lechner-Schoner, T; Patsch, JR; Rauchenzauner, M; Strauss, R, 2006) |
| "5% in mean body weight over the course of the study in the mirtazapine group that appeared to reach a plateau at 3 weeks, while no increase was observed in the placebo group." | 5.10 | The effects of mirtazapine on plasma lipid profiles in healthy subjects. ( Ekstrom, RD; Esposito, SM; Ford, AL; Golden, RN; Nicholas, LM, 2003) |
| "To investigate the effect of mirtazapine on tumor growth, food intake, body weight, and nutritional status in gemcitabine-induced mild cachexia." | 3.78 | Intervention of mirtazapine on gemcitabine-induced mild cachexia in nude mice with pancreatic carcinoma xenografts. ( Jia, L; Jiang, SM; Wu, JH, 2012) |
| "To investigate the effects of mirtazapine and fluoxetine, representatives of the noradrenergic and specific serotonergic antidepressant (NaSSA) and selective serotonin reuptake inhibitor (SSRI) antidepressant respectively, on body weight, ingestive behavior, locomotor activity and tumor growth of human pancreatic carcinoma xenografts in nude mice." | 3.74 | Effect of antidepressants on body weight, ethology and tumor growth of human pancreatic carcinoma xenografts in nude mice. ( Jia, L; Li, YY; Shang, YY, 2008) |
| "To report the use of Mirtazapine in the treatment of anorexia nervosa with depression primarily regarding its propensity for weight gain." | 3.74 | Mirtazapine for anorexia nervosa with depression. ( Baharudin, A; Daud, TI; Jaafar, NR; Rahman, FN, 2007) |
| "Mianserin (60 mg daily) was compared with chlorimipramine (150 mg daily) in the treatment of 145 depressed in- and outpatients in four centres." | 2.65 | A double-blind multicentre trial comparing the efficacy and side-effects of mianserin and chlorimipramine in depressed in- and outpatients. ( Barres, M; Blum, A; Charbaut, J; Israel, L; Kammerer, T; Molczadzki, M; Pinder, RM; Rigaud, A; Stulemeijer, SM, 1980) |
| "Mianserin was considered to be an effective antidepressant." | 2.65 | Multicentre evaluation of mianserin in depressive illness. ( Burrows, GD; Marriott, P; Norman, TR, 1981) |
| " Weight gain is the most commonly reported side-effect of mirtazapine, although there is evidence to suggest that this is not a significant problem during long-term treatment." | 2.41 | Tolerability and safety aspects of mirtazapine. ( Nutt, DJ, 2002) |
| "Changes in body weight can affect the overall health of an older patient and should not be considered a normal part of the aging process." | 1.40 | Potential role of mirtazapine in underweight older adults. ( Avena-Woods, C; Hilas, O, 2014) |
| "Mirtazapine is an antidepressant approved for the treatment of major depressive disorder." | 1.38 | Antidepressant use in underweight older adults. ( Avena-Woods, C; Hilas, O, 2012) |
| "Pretreatment with desipramine and mianserin in combination induced the most intense 5-HT syndrome and the greatest fall in colonic temperature after injection of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT)." | 1.29 | Chronic, combined treatment with desipramine and mianserin: enhanced 5-HT1A receptor function and altered 5-HT1A/5-HT2 receptor interaction in rats. ( Lund, A; Mjellem, N, 1993) |
| "Saccharin intake was increased with lithium treatment as was total caloric intake with sucrose available." | 1.27 | Effects of chronic lithium, amitriptyline and mianserin on glucoregulation, corticosterone and energy balance in the rat. ( Atrens, DM; Gleeson, RM; Higson, FM; Smythe, GA; Storlien, LH, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (25.00) | 18.7374 |
| 1990's | 3 (10.71) | 18.2507 |
| 2000's | 11 (39.29) | 29.6817 |
| 2010's | 7 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hilas, O | 2 |
| Avena-Woods, C | 2 |
| Jia, L | 2 |
| Shang, YY | 1 |
| Li, YY | 1 |
| Terao, T | 1 |
| Riechelmann, RP | 1 |
| Burman, D | 1 |
| Tannock, IF | 1 |
| Rodin, G | 1 |
| Zimmermann, C | 1 |
| Safer, DL | 1 |
| Darcy, AM | 1 |
| Lock, J | 1 |
| Laino, CH | 1 |
| Fonseca, C | 1 |
| Sterin-Speziale, N | 1 |
| Slobodianik, N | 1 |
| Reinés, A | 1 |
| Dolev, Z | 1 |
| Jiang, SM | 1 |
| Wu, JH | 1 |
| Nutt, DJ | 1 |
| Kraus, T | 1 |
| Haack, M | 1 |
| Schuld, A | 2 |
| Hinze-Selch, D | 1 |
| Koethe, D | 1 |
| Pollmächer, T | 2 |
| Nicholas, LM | 1 |
| Ford, AL | 1 |
| Esposito, SM | 1 |
| Ekstrom, RD | 1 |
| Golden, RN | 1 |
| Schmid, DA | 1 |
| Wichniak, A | 1 |
| Uhr, M | 1 |
| Ising, M | 1 |
| Brunner, H | 1 |
| Held, K | 1 |
| Weikel, JC | 1 |
| Sonntag, A | 1 |
| Steiger, A | 1 |
| Himmerich, H | 1 |
| Fulda, S | 1 |
| Schaaf, L | 1 |
| Beitinger, PA | 1 |
| Shen, J | 1 |
| Chung, SA | 1 |
| Kayumov, L | 1 |
| Moller, H | 1 |
| Hossain, N | 1 |
| Wang, X | 1 |
| Deb, P | 1 |
| Sun, F | 1 |
| Huang, X | 1 |
| Novak, M | 1 |
| Appleton, D | 1 |
| Shapiro, CM | 1 |
| Laimer, M | 1 |
| Kramer-Reinstadler, K | 1 |
| Rauchenzauner, M | 1 |
| Lechner-Schoner, T | 1 |
| Strauss, R | 1 |
| Engl, J | 1 |
| Deisenhammer, EA | 1 |
| Hinterhuber, H | 1 |
| Patsch, JR | 1 |
| Ebenbichler, CF | 1 |
| Nagata, T | 1 |
| Ono, K | 1 |
| Nakayama, K | 1 |
| Jaafar, NR | 1 |
| Daud, TI | 1 |
| Rahman, FN | 1 |
| Baharudin, A | 1 |
| Harris, B | 1 |
| Harper, M | 1 |
| Riise, IS | 1 |
| Holm, P | 1 |
| Pinder, RM | 1 |
| Blum, A | 1 |
| Stulemeijer, SM | 1 |
| Barres, M | 1 |
| Molczadzki, M | 1 |
| Rigaud, A | 1 |
| Charbaut, J | 1 |
| Israel, L | 1 |
| Kammerer, T | 1 |
| Marriott, P | 1 |
| Burrows, GD | 1 |
| Norman, TR | 1 |
| Cording-Tömmel, C | 1 |
| von Zerssen, D | 1 |
| Williams, W | 1 |
| Peeters, BW | 1 |
| van der Heijden, R | 1 |
| Gubbels, DG | 1 |
| Vanderheyden, PM | 1 |
| Lund, A | 1 |
| Mjellem, N | 1 |
| Neal, BS | 1 |
| Sparber, SB | 1 |
| Storlien, LH | 1 |
| Higson, FM | 1 |
| Gleeson, RM | 1 |
| Smythe, GA | 1 |
| Atrens, DM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Mirtazapine Versus Placebo on Appetite, Nutritional Status and Quality of Life in Non-small Cell Lung cáncer Patients With Anorexia; Randomized Double-blind Clinical Trial.[NCT04748523] | 86 participants (Actual) | Interventional | 2018-08-29 | Completed | |||
| Randomized, Double-blind Clinical Trial of the Use of Mirtazapine Versus Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.[NCT03283488] | Phase 2 | 52 participants (Actual) | Interventional | 2019-03-26 | Completed | ||
| Antidepressant Response to a Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder[NCT00385437] | Phase 2 | 16 participants | Interventional | 2003-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for mianserin and Body Weight
| Article | Year |
|---|---|
Tolerability and safety aspects of mirtazapine.
Topics: Adrenergic alpha-Antagonists; Antidepressive Agents; Body Weight; Depressive Disorder; Humans; Mians | 2002 |
8 trials available for mianserin and Body Weight
| Article | Year |
|---|---|
Phase II trial of mirtazapine for cancer-related cachexia and anorexia.
Topics: Aged; Aged, 80 and over; Anorexia; Antidepressive Agents, Tricyclic; Appetite; Body Weight; Cachexia | 2010 |
Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine.
Topics: Adult; Aged; Antipsychotic Agents; Body Mass Index; Body Weight; Cross-Over Studies; Cyclohexanols; | 2002 |
The effects of mirtazapine on plasma lipid profiles in healthy subjects.
Topics: Adult; Antidepressive Agents, Tricyclic; Body Weight; Cholesterol; Coronary Disease; Dose-Response R | 2003 |
Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine.
Topics: Adrenocorticotropic Hormone; Adult; Animals; Antidepressive Agents, Tricyclic; Area Under Curve; Bod | 2006 |
Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine.
Topics: Adult; Affect; Antidepressive Agents, Tricyclic; Body Weight; Depressive Disorder, Major; Drug Admin | 2006 |
Effect of mirtazapine treatment on body composition and metabolism.
Topics: Adipose Tissue; Adult; Antidepressive Agents, Tricyclic; Blood Glucose; Body Composition; Body Fat D | 2006 |
A double-blind multicentre trial comparing the efficacy and side-effects of mianserin and chlorimipramine in depressed in- and outpatients.
Topics: Adolescent; Adult; Aged; Body Weight; Clinical Trials as Topic; Clomipramine; Depressive Disorder; D | 1980 |
Multicentre evaluation of mianserin in depressive illness.
Topics: Adult; Body Weight; Clinical Trials as Topic; Constipation; Depressive Disorder; Dibenzazepines; Fem | 1981 |
19 other studies available for mianserin and Body Weight
| Article | Year |
|---|---|
Potential role of mirtazapine in underweight older adults.
Topics: Aged; Antidepressive Agents, Tricyclic; Appetite; Body Weight; Humans; Mianserin; Mirtazapine; Quali | 2014 |
Effect of antidepressants on body weight, ethology and tumor growth of human pancreatic carcinoma xenografts in nude mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Body Weight; Ca | 2008 |
Unusual weight fluctuation under corticosteroid and psychotropic treatment.
Topics: Adult; Anti-Inflammatory Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; App | 2008 |
Use of mirtazapine in an adult with refractory anorexia nervosa and comorbid depression: a case report.
Topics: Anorexia Nervosa; Antidepressive Agents, Tricyclic; Body Weight; Depressive Disorder, Major; Female; | 2011 |
Potentiation of omega-3 fatty acid antidepressant-like effects with low non-antidepressant doses of fluoxetine and mirtazapine.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Body Weight; Dose-Response Relationship, Drug; Dru | 2010 |
Case series of perimenopausal women with insomnia treated with mirtazapine followed by prolonged-release melatonin add-on and monotherapy.
Topics: Antidepressive Agents, Tricyclic; Body Weight; Delayed-Action Preparations; Dose-Response Relationsh | 2011 |
Intervention of mirtazapine on gemcitabine-induced mild cachexia in nude mice with pancreatic carcinoma xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Cachexia; Carcinoma; Cell Line, Tumor; Deoxyc | 2012 |
Antidepressant use in underweight older adults.
Topics: Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents; Appetite; Body Mass Index; Body Weigh | 2012 |
Changes in weight and glucose tolerance during treatment with mirtazapine.
Topics: Antidepressive Agents, Tricyclic; Blood Glucose; Body Weight; Depressive Disorder; Female; Glucose T | 2006 |
Anorexia nervosa with chronic episodes for more than 30 years in a patient with a comorbid schizotypal personality disorder.
Topics: Anorexia Nervosa; Antidepressive Agents, Second-Generation; Benzodiazepines; Body Weight; Bulimia; C | 2007 |
Mirtazapine for anorexia nervosa with depression.
Topics: Adolescent; Anorexia Nervosa; Antidepressive Agents, Tricyclic; Body Weight; Cognitive Behavioral Th | 2007 |
Unusual appetites in patients on mianserin.
Topics: Appetite; Body Weight; Depression; Dibenzazepines; Female; Humans; Male; Mianserin; Middle Aged | 1980 |
Concomitant isocarboxazid/mianserin treatment of major depressive disorder.
Topics: Adult; Aged; Body Weight; Depressive Disorder; Dibenzazepines; Drug Interactions; Drug Therapy, Comb | 1984 |
Mianserin and maprotiline as compared to amitriptyline in severe endogenous depression. A new methodological approach to the clinical evaluation of the efficacy of antidepressants.
Topics: Adult; Amitriptyline; Anthracenes; Body Weight; Depressive Disorder; Dibenzazepines; Drug Evaluation | 1982 |
Possible use of mianserin in cases of unacceptable weight gain due to tricyclic anti-depressant therapy.
Topics: Adult; Amitriptyline; Body Weight; Depression; Dibenzazepines; Female; Humans; Mianserin | 1980 |
Effects of chronic antidepressant treatment on the hypothalamic-pituitary-adrenal axis of Wistar rats.
Topics: Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Body Weight; Corticosterone; Hippocampus; | 1994 |
Chronic, combined treatment with desipramine and mianserin: enhanced 5-HT1A receptor function and altered 5-HT1A/5-HT2 receptor interaction in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amphetamines; Animals; Behavior, Animal; Body Temperature; B | 1993 |
Long-term effects of neonatal exposure to isobutylmethylxanthine. I. Retardation of learning with antagonism by mianserin.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Animals, Newborn; Body Weight; Cognition; Conditioning, Operan | 1991 |
Effects of chronic lithium, amitriptyline and mianserin on glucoregulation, corticosterone and energy balance in the rat.
Topics: Amitriptyline; Animals; Blood Glucose; Body Weight; Corticosterone; Dibenzazepines; Drinking; Eating | 1985 |